PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1799527
PUBLISHER: Bizwit Research & Consulting LLP | PRODUCT CODE: 1799527
The Global Image-Guided Radiation Therapy (IGRT) Market is valued at approximately USD 2.00 billion in 2024 and is poised to expand at a compound annual growth rate (CAGR) of over 5.20% during the forecast period 2025-2035. IGRT represents a sophisticated cancer treatment modality where imaging technologies are seamlessly integrated with radiation therapy to enhance precision in targeting tumors while safeguarding healthy tissue. Over the years, oncology practices have embraced IGRT to minimize collateral damage during treatment, improve tumor localization, and enable adaptive radiotherapy. The market's momentum is strongly driven by the surge in cancer prevalence worldwide, increasing adoption of precision medicine, and ongoing technological innovations in imaging and radiotherapy platforms. The ability of IGRT to adapt to tumor movement in real-time and deliver higher treatment accuracy has made it a cornerstone in modern oncology protocols.
The rising incidence of various cancers, coupled with a growing geriatric population, has amplified the demand for advanced radiotherapy solutions. This surge has been accompanied by a notable rise in healthcare expenditure and investments in oncology infrastructure, particularly in emerging economies. According to the International Agency for Research on Cancer (IARC), cancer cases are expected to grow significantly by 2040, reinforcing the need for advanced treatment systems like IGRT. Furthermore, strategic collaborations between technology providers and healthcare institutions are facilitating the development of AI-enabled imaging and adaptive therapy systems, opening new avenues for market expansion. Nonetheless, the high capital cost of IGRT systems and the scarcity of trained professionals in low-resource settings remain potential barriers to wider adoption in certain regions.
From a geographical perspective, North America commanded the largest share of the IGRT market in 2024, underpinned by its robust healthcare infrastructure, early adoption of cutting-edge medical technologies, and extensive R&D investments by both public and private entities. The U.S., in particular, benefits from favorable reimbursement frameworks and a high concentration of specialized oncology centers. Europe follows closely, propelled by growing awareness of personalized cancer therapies and government-backed cancer control initiatives. Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period, driven by rising cancer incidence, expanding access to advanced diagnostic and therapeutic services, and substantial investments in healthcare modernization in countries like China, India, and Japan. The ongoing shift toward value-based care and adoption of telehealth-integrated oncology services in the region is likely to further accelerate IGRT deployment.
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below: